BEVERAGE-BOARD

[ash111]

SPHS,liking. 16.9m O/S,(cap is 14m), 13.2m Cash on Hand. June 2015 presentation on website- "To date PRX302 appears safe and well tolerated"

Funded to P2 Localized prostate cancer(huge mrkt), and P3 BPH(huge mrkt) results.

CANF is another undervalued biotech company. 2B market potential for CF102 and CF101 DATA in 10 days.CANF was trading 7+ last week dropped only due to the whole bio(s) Sector Weakness.if we get another solid data for CF101 as well,this will be trading way over 7 imo

I think the company has something very positive to say,why? April 27, 2015, Can-Fite Reports Positive Results from Further Analysis of Phase II/III Psoriasis Trial

Data suggest CF101 as potential first-line systemic therapy for patients with moderate-severe psoriasis; Company prepares protocol of next advanced psoriasis trial

http://ir.canfite.com/press-releases/detail/716/can-fite-reports-positive-results-from-further-analysis-of-phase-iiiii-psoriasis-trial